Search information pages
About Molecular Autism
This page includes information about the aims and scope of Molecular Autism, editorial policies, open access and article-processing charges, the peer review process and other information. For details of how to prepare and submit a manuscript through the online submission system, please see the instructions for authors.
Aims & scope
Molecular Autism is a peer-reviewed, online open access journal that publishes high-quality basic, translational and clinical research that has relevance to the etiology, pathobiology, or treatment of autism and related neurodevelopmental conditions. Research that includes integration across levels is encouraged. Molecular Autism publishes empirical studies, reviews, and brief communications.
We encourage submission of empirical studies of autism from a range of fields including (but not restricted to) genetics, molecular neurobiology, neuropathology, neuroimaging, cognitive neuroscience, epidemiology, and biomarker discovery. Molecular Autism also publishes articles on screening, diagnosis and classification, including articles that consider subgrouping to refine our understanding of basic mechanisms. Intervention studies are also welcome, especially when considered with respect to revealing causal mechanisms.
Although the primary focus is on conditions on the autism spectrum (including Asperger syndrome), the scope encompasses molecular research into related neurodevelopmental conditions such as specific language impairment, dyspraxia, and specific or general developmental delays; and into related medical syndromes such as fragile X syndrome, tuberous sclerosis, and Rett syndrome.
Molecular Autism also considers articles with no molecular data but which, in the long-term, may close the gap from molecule to behavior in autism. The journal welcomes reports and reviews of good science that proceed from either end of this complex chain of events: from molecule upwards, or from behavior downwards. Reports and reviews can be basic and/or translational.
All articles published by Molecular Autism are made freely and permanently accessible online immediately upon publication, without subscription charges or registration barriers. Further information about open access can be found here.
Authors of articles published in Molecular Autism are the copyright holders of their articles and have granted to any third party, in advance and in perpetuity, the right to use, reproduce or disseminate the article, according to the BioMed Central copyright and license agreement.
For authors who are US government employees or are prevented from being copyright holders for similar reasons, BioMed Central can accommodate non-standard copyright lines. Please contact us if further information is needed.
Open access publishing is not without costs. Molecular Autism therefore levies an article-processing charge of £1370/$2145/€1745 for each article accepted for publication. If the corresponding author's institution is a Member, the cost of the article-processing charge is covered by the membership, and no further charge is payable. In the case of authors whose institutions are Supporter Members, however, a discounted article-processing charge is payable by the author. We routinely waive charges for authors from low-income countries. For other countries, article-processing charge waivers or discounts are granted on a case-by-case basis to authors with insufficient funds. Authors can request a waiver or discount during the submission process. For further details, see our article-processing charge page.
All articles published in Molecular Autism are included in PubMed, the most widely used biomedical bibliographic database service, which is run by the US National Library of Medicine. Other bibliographic databases that index articles published in Molecular Autism include:
- Biological Abstracts
- Google Scholar
- Journal Citation Reports/Science Edition
- PubMed Central
- Science Citation Index Expanded
The full text of all research articles is deposited in PubMed Central, the US National Library of Medicine's full-text repository of life science literature, and other digital archives including e-Depot (The Netherlands).
The full text of all research articles published by BioMed Central is also available on SpringerLink.
Molecular Autism is tracked by Thomson Reuters (ISI) and has an Impact Factor of 5.41.
Publication and peer review process
Criteria for publication
Molecular Autism considers the following types of articles:
- Commentaries: short, focused and opinionated articles on any subject within the journal's scope. These articles are usually related to a contemporary issue, such as recent research findings, and are often written by opinion leaders invited by the Editorial Board.
- Letter to the Editor: these can take three forms: a substantial re-analysis of a previously published article, or a substantial response to such a re-analysis from the authors of the original publication, or an article that may not cover 'standard research' but that may be relevant to readers.
- Methodology: presentation of a new experimental method, test or procedure. The method described may either be completely new, or may offer a better version of an existing method. The article should describe a demonstrable advance on what is currently available.
- Research: reports of data from original research. These articles will form the major content of the journal.
- Reviews: summaries of recent insights in specific research areas within the scope of Molecular Autism. These articles are often written by opinion leaders invited by the Editorial Board but can also be submitted following editorial acceptance of an author's proposal.
- Short reports: brief reports of data from original research.
- Viewpoints: short opinion pieces focusing on the latest high-impact research.
Molecular Autism does not generally consider case reports, unsolicited reviews or medical hypotheses.
Manuscripts are reviewed by internationally recognized experts in the field, selected in part from our Editorial Board. Reviews are rapid and the suitability of a paper for publication will be assessed solely on criteria of scientific excellence. Final decisions will be made by the Editors-in-Chief.
Authors will be able to check the progress of their manuscript through the submission system at any time by logging into My Molecular Autism, a personalized section of the site.
High-quality, bound reprints can be purchased for all articles published. Please see our reprints website for further information about ordering reprints.
Molecular Autism will consider supplements based on proceedings (full articles or meeting abstracts), reviews or research. All articles submitted for publication in supplements are subject to peer review. Published supplements are fully searchable and freely accessible online and can also be produced in print. All full length articles (proceedings, reviews or research articles) are indexed by PubMed. PubMed displays the title of the supplement only in the case of meeting abstract collections. For further information, please contact us.
All manuscripts submitted to Molecular Autism should adhere to BioMed Central's editorial policies.
Citing articles in Molecular Autism
Articles in Molecular Autism should be cited in the same way as articles in a traditional journal. Because articles are not printed, they do not have page numbers; instead, they are given a unique article number.
Article citations follow this format:
Authors: Title. Mol Autism [year], [volume number]:[article number].
e.g. Roberts LD, Hassall DG, Winegar DA, Haselden JN, Nicholls AW, Griffin JL: Increased hepatic oxidative metabolism distinguishes the action of Peroxisome Proliferator-Activated Receptor delta from Peroxisome Proliferator-Activated Receptor gamma in the Ob/Ob mouse. Mol Autism 2009, 1:115.
refers to article 115 from Volume 1 of the journal.
Why publish your article in Molecular Autism?
Molecular Autism's open access policy allows maximum visibility of articles published in the journal as they are available to a wide, global audience. Articles that have been especially highly accessed are highlighted with a 'Highly accessed' graphic, which appears on the journal's contents pages and search results.
Speed of publication
Molecular Autism offers a fast publication schedule whilst maintaining rigorous peer review; all articles must be submitted online, and peer review is managed fully electronically (articles are distributed in PDF form, which is automatically generated from the submitted files). Articles will be published with their final citation after acceptance, in both fully browsable web form, and as a formatted PDF; the article will then be available through Molecular Autism, BioMed Central and PubMed Central and will also be included in PubMed.
Online publication in Molecular Autism gives authors the opportunity to publish large datasets, large numbers of color illustrations and moving pictures, to display data in a form that can be read directly by other software packages so as to allow readers to manipulate the data for themselves, and to create all relevant links (for example, to PubMed, to sequence and other databases, and to other articles).
Promotion and press coverage
Articles published in Molecular Autism are included in article alerts and regular email updates. Some may be included in abstract books mailed to academics and are highlighted on Molecular Autism's pages and on the BioMed Central homepage.
In addition, articles published in Molecular Autism may be promoted by press releases to the general or scientific press. These activities increase the exposure and number of accesses for articles published in Molecular Autism. A list of articles recently press-released by journals published by BioMed Central is available here.
Authors of articles published in Molecular Autism retain the copyright of their articles and are free to reproduce and disseminate their work (for further details, see the BioMed Central copyright policy and license agreement).
For further information about the advantages of publishing in a journal from BioMed Central, please click here.